Do analysts prefer BLRX or AKAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, BLRX or AKAN?

BioLineRx has higher revenue and earnings than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioLineRx $1.40M 8.65 -$1.17M -$1.92 N/A Akanda $260K 10.95 -$45.65M N/A N/A

Is BLRX or AKAN more profitable?

Akanda has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. Akanda's return on equity of 0.00% beat BioLineRx's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -563.70% -37.73% -19.42% Akanda N/A N/A N/A

Do analysts rate AKAN or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, AKAN or COCP?

Cocrystal Pharma has lower revenue, but higher earnings than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akanda $260K 10.95 -$45.65M N/A N/A Cocrystal Pharma $225K 63.54 -$8.83M -$0.73 N/A

Is AKAN or COCP more profitable?

Akanda's return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Akanda N/A N/A N/A Cocrystal Pharma N/A -150.61% -97.86%

Do analysts prefer CALC or AKAN?

CalciMedica currently has a consensus price target of $10.00, suggesting a potential upside of 1,288.89%. Given CalciMedica's stronger consensus rating and higher possible upside, equities research analysts clearly believe CalciMedica is more favorable than Akanda. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CALC or AKAN?

CalciMedica has higher earnings, but lower revenue than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CalciMedica N/A N/A -$29.56M -$1.31 N/A Akanda $260K 10.95 -$45.65M N/A N/A

Is CALC or AKAN more profitable?

Akanda's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% Akanda N/A N/A N/A

Do analysts recommend FNCH or AKAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, FNCH or AKAN?

Akanda has higher revenue and earnings than Finch Therapeutics Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A Akanda $260K 10.95 -$45.65M N/A N/A

Is FNCH or AKAN more profitable?

Akanda's return on equity of 0.00% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Akanda N/A N/A N/A

Do analysts prefer AKAN or PHIO?

Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,202.33%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Akanda. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, AKAN or PHIO?

Phio Pharmaceuticals has lower revenue, but higher earnings than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akanda $260K 10.95 -$45.65M N/A N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A

Is AKAN or PHIO more profitable?

Akanda's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Akanda N/A N/A N/A Phio Pharmaceuticals N/A -77.34% -70.87%

Akanda (AKAN) Competitors

$5.27 +0.24 (+4.77%)

As of 03:33 PM Eastern

Compare

AKAN vs. BLRX, COCP, CALC, FNCH, and PHIO

Should you buy Akanda stock or one of its competitors? MarketBeat compares Akanda with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akanda include BioLineRx (BLRX), Cocrystal Pharma (COCP), CalciMedica (CALC), Finch Therapeutics Group (FNCH), and Phio Pharmaceuticals (PHIO).

How does Akanda compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and Akanda (NASDAQ:AKAN) are related small-cap companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

BioLineRx has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Akanda has a beta of 14.12, meaning that its stock price is 1,312% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Akanda has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. Akanda's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
Akanda	N/A	N/A	N/A

In the previous week, BioLineRx had 1 more articles in the media than Akanda. MarketBeat recorded 1 mentions for BioLineRx and 0 mentions for Akanda. BioLineRx's average media sentiment score of 0.00 equaled Akanda'saverage media sentiment score.

Company	Overall Sentiment
BioLineRx	Neutral
Akanda	Neutral

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 20.4% of Akanda shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioLineRx has higher revenue and earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.40M	8.65	-$1.17M	-$1.92	N/A
Akanda	$260K	10.95	-$45.65M	N/A	N/A

Summary

Akanda beats BioLineRx on 6 of the 10 factors compared between the two stocks.

How does Akanda compare to Cocrystal Pharma?

Akanda (NASDAQ:AKAN) and Cocrystal Pharma (NASDAQ:COCP) are related small-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cocrystal Pharma has lower revenue, but higher earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akanda	$260K	10.95	-$45.65M	N/A	N/A
Cocrystal Pharma	$225K	63.54	-$8.83M	-$0.73	N/A

In the previous week, Cocrystal Pharma had 2 more articles in the media than Akanda. MarketBeat recorded 2 mentions for Cocrystal Pharma and 0 mentions for Akanda. Akanda's average media sentiment score of 0.00 equaled Cocrystal Pharma'saverage media sentiment score.

Company	Overall Sentiment
Akanda	Neutral
Cocrystal Pharma	Neutral

Akanda's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akanda	N/A	N/A	N/A
Cocrystal Pharma	N/A	-150.61%	-97.86%

Akanda has a beta of 14.12, suggesting that its share price is 1,312% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

1.0% of Akanda shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 20.4% of Akanda shares are held by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Cocrystal Pharma beats Akanda on 5 of the 9 factors compared between the two stocks.

How does Akanda compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and Akanda (NASDAQ:AKAN) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

1.0% of Akanda shares are held by institutional investors. 28.3% of CalciMedica shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CalciMedica has higher earnings, but lower revenue than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Akanda	$260K	10.95	-$45.65M	N/A	N/A

CalciMedica currently has a consensus price target of $10.00, suggesting a potential upside of 1,288.89%. Given CalciMedica's stronger consensus rating and higher possible upside, equities research analysts clearly believe CalciMedica is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, CalciMedica's average media sentiment score of 0.00 equaled Akanda'saverage media sentiment score.

Company	Overall Sentiment
CalciMedica	Neutral
Akanda	Neutral

CalciMedica has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Akanda has a beta of 14.12, suggesting that its stock price is 1,312% more volatile than the broader market.

Akanda's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
Akanda	N/A	N/A	N/A

Summary

CalciMedica and Akanda tied by winning 5 of the 10 factors compared between the two stocks.

How does Akanda compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Akanda (NASDAQ:AKAN) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Akanda has higher revenue and earnings than Finch Therapeutics Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Akanda	$260K	10.95	-$45.65M	N/A	N/A

In the previous week, Finch Therapeutics Group's average media sentiment score of 0.00 equaled Akanda'saverage media sentiment score.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Akanda	Neutral

Akanda's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Akanda	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Finch Therapeutics Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Akanda has a beta of 14.12, meaning that its stock price is 1,312% more volatile than the broader market.

Summary

Akanda beats Finch Therapeutics Group on 6 of the 8 factors compared between the two stocks.

How does Akanda compare to Phio Pharmaceuticals?

Akanda (NASDAQ:AKAN) and Phio Pharmaceuticals (NASDAQ:PHIO) are related small-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

1.0% of Akanda shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 20.4% of Akanda shares are held by company insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Akanda has a beta of 14.12, suggesting that its stock price is 1,312% more volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market.

Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,202.33%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Akanda.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Akanda's average media sentiment score of 0.00 equaled Phio Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Akanda	Neutral
Phio Pharmaceuticals	Neutral

Akanda's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akanda	N/A	N/A	N/A
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

Phio Pharmaceuticals has lower revenue, but higher earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akanda	$260K	10.95	-$45.65M	N/A	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

Summary

Akanda and Phio Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

Get Akanda News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKAN vs. The Competition

Export

Metric	Akanda	Diversified Telecommunication Services Industry	Communication Services Sector	NASDAQ Exchange
Market Cap	$2.85M	$34.40B	$32.68B	$12.84B
Dividend Yield	N/A	7.04%	5.32%	9.78%
P/E Ratio	N/A	10.14	17.58	25.44
Price / Sales	10.95	21.02	296.69	79.78
Price / Cash	N/A	18.10	19.99	50.79
Price / Book	-0.21	4.18	10.94	6.07
Net Income	-$45.65M	$1.11B	$1.11B	$348.34M
7 Day Performance	-17.53%	0.65%	1.00%	3.07%
1 Month Performance	-56.48%	-0.05%	-0.72%	-3.04%
1 Year Performance	-93.00%	4.90%	5.11%	20.78%

Akanda Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKAN Akanda	0.9387 of 5 stars	$5.27 +4.8%	N/A	-93.2%	$2.85M	$260K	N/A	110	Gap Up
BLRX BioLineRx	0.2592 of 5 stars	$2.75 -2.1%	N/A	-30.1%	$12.02M	$1.18M	N/A	40	News Coverage Upcoming Earnings Gap Up
COCP Cocrystal Pharma	0.2742 of 5 stars	$0.87 -6.9%	N/A	-38.2%	$12.00M	N/A	N/A	10	Upcoming Earnings
CALC CalciMedica	2.8997 of 5 stars	$0.74 +3.5%	$10.00 +1,246.3%	-75.3%	$11.74M	N/A	N/A	30	Positive News Upcoming Earnings
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKAN) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akanda (AKAN) Competitors

AKAN vs. BLRX, COCP, CALC, FNCH, and PHIO

How does Akanda compare to BioLineRx?

Summary

How does Akanda compare to Cocrystal Pharma?

Summary

How does Akanda compare to CalciMedica?

Summary

How does Akanda compare to Finch Therapeutics Group?

Summary

How does Akanda compare to Phio Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKAN vs. The Competition

Akanda Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akanda (AKAN) Competitors

AKAN vs. BLRX, COCP, CALC, FNCH, and PHIO

How does Akanda compare to BioLineRx?

Which has more risk and volatility, BLRX or AKAN?

Do analysts prefer BLRX or AKAN?

Is BLRX or AKAN more profitable?

Does the media prefer BLRX or AKAN?

Do insiders and institutionals have more ownership in BLRX or AKAN?

Which has better valuation and earnings, BLRX or AKAN?

Summary

How does Akanda compare to Cocrystal Pharma?

Do analysts rate AKAN or COCP?

Which has stronger valuation and earnings, AKAN or COCP?

Does the media prefer AKAN or COCP?

Is AKAN or COCP more profitable?

Which has more risk & volatility, AKAN or COCP?

Do insiders & institutionals believe in AKAN or COCP?

Summary

How does Akanda compare to CalciMedica?

Do insiders & institutionals hold more shares of CALC or AKAN?

Which has stronger earnings and valuation, CALC or AKAN?

Do analysts prefer CALC or AKAN?

Does the media favor CALC or AKAN?

Which has more volatility & risk, CALC or AKAN?

Is CALC or AKAN more profitable?

Summary

How does Akanda compare to Finch Therapeutics Group?

Do insiders & institutionals have more ownership in FNCH or AKAN?

Which has higher earnings & valuation, FNCH or AKAN?

Does the media favor FNCH or AKAN?

Is FNCH or AKAN more profitable?

Do analysts recommend FNCH or AKAN?

Which has more volatility and risk, FNCH or AKAN?

Summary

How does Akanda compare to Phio Pharmaceuticals?

Do insiders and institutionals believe in AKAN or PHIO?

Which has more volatility and risk, AKAN or PHIO?

Do analysts prefer AKAN or PHIO?

Does the media refer more to AKAN or PHIO?

Is AKAN or PHIO more profitable?

Which has stronger valuation and earnings, AKAN or PHIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKAN vs. The Competition

Akanda Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools